LB Pharmaceuticals Inc (LBRX)
LBRXNASDAQ-GMBiotechnology: Pharmaceutical Preparations
$44.94
-0.1800 (-0.40%) today
Closed, Nov 10, 4:00 PM ET
- Market cap
- $1.45bn
- P/E
- –
- EPS, last 4 quarters
- $-4.62
- Dividend yield
- –
- Day range
- –
- 52-week range
- $14.32 to $50.16
- Average volume
- 374.2k
- Previous close
- $45.12
Analysts
10 coveringBuy9 buy, 1 hold, 0 sell
Targets a year out average $60.70, +35.1% from here
Earnings
next estimate $-1.72Next report
Dec 2025
0.0%
Mar 2026
+10.7%
Jun 2026
-103.6%
Sep 2026
-11.2%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$13.87m | -$22.10m | -$53.91m | -$62.50m |
| Net income | -$11.47m | -$19.05m | -$51.60m | -$59.07m |
News
8 latest- LB Pharmaceuticals Eyes 2027 Phase III Data for LB-102 in SchizophreniaMarketBeat · Oct 27, 2026
- Guggenheim Initiates Coverage of LB Pharmaceuticals at BuyFintel · Oct 6, 2026
- LB Pharmaceuticals Appoints Susan Kozauer As CMO RTTNews · Sep 15, 2026
- LB Pharmaceuticals Names Joseph Miller CFO RTTNews · Sep 3, 2026
- LBRX Crosses Above Average Analyst TargetBNK Invest · Aug 19, 2026
- LB Pharmaceuticals Accelerates LB-102 Schizophrenia Program; Phase 3 Data Expected In 1H27 RTTNews · Aug 11, 2026
- Top Biotech Gainers: SPRC On Watch, AVTR, NEO Boost Full-Year Outlook, SMTI Scooped Up RTTNews · Jul 29, 2026
- Biotech Stocks At 52-Week Highs - INCY Rises With Q2 Results, PLSE, SI, BVS, LBRX RTTNews · Jul 29, 2026
The company
LB Pharmaceuticals is a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders. The Company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the Company believes has the opportunity to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States . LB-102, if approved, has the potential to become a mainstay of psychiatric practice by offering balanced clinical activity and tolerability along with simplicity of use that provides a potentially attractive alternative to branded and generic therapeutics for the treatment of a broad range of neuropsychiatric diseases.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- lbpharma.us
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.